Skip to content
Clear Signal
CompaniesAnnouncementOpen the first report

FDA grants accelerated approval to camizestrant for ESR1-mutated advanced breast cancer.

  • FDA
  • camizestrant
  • AstraZeneca
Head start23m
fda.gov
KalshiWill the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?36¢to97¢

Markets

PriceMoveHead startNow

Reports

  1. 0sFirstfda.gov
  2. +6m 26sRepeatedLiveSquawk on X
  3. +11mRepeatedFirst Squawk on X
  4. +23m36¢to97¢
  5. +27mNew detailU.S. Food and Drug Administration
  6. +3h 36mOfficialAstraZeneca US press release on astrazen
  7. +3dOfficialAstraZeneca's filing on SEC EDGAR
UTC